CMS

China Medical System Holdings Limited, an investment holding company manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters.

Its portfolio also includes XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure, Plendil, a felodipine sustained release tablets for hypertension, and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate depression Gastroenterology products, such as METOJECT, a methotrexate injection to treat severe recalcitrant disabling psoriasis and rheumatoid arthritis.

Its portfolio also includes LUMEBLUE, a methylthioninium chloride enteric-coated sustained-release tablets for colorectal lesion visualization, Salofalk for ulcerative colitis and Crohn's disease, Bioflor, a saccharomyces boulardii sachets for diarrhea, Combizym and Cidine for digestive enzymes, and Ursofalk, a ursodeoxycholic acid capsules to treat cholesterol gallstones.

Additionally, it offers dermatology products, including ILUMETRI, a tildrakizumab injection for the treatment of plaque psoriasis. Its portfolio also includes Aethoxysklerol, a polidocanol injection for sclerotherapy of various varicose veins, Hirudoid, a mucopolysaccharide polysulfate cream to treat blunt traumata, skin heling soothing product, and Hirudoid for acne-prone skin care, prevention, and enhancement of acne